Table 1.

Baseline demographics and disease characteristics for patients in BUILDER-1 part 1 (placebo-controlled phase, 12 weeks)

	Placebo n=51	TCZ 8 mg/kg n=51
Age, years, mean (SD)	42.7 (12.6)	41.6 (11.2)
Male, n (%)	40 (78)	36 (71)
Geographical region, n (%)
North America	11 (22)	12 (24)
Rest of world	40 (78)	39 (76)
Positive HLA-B27 status, n (%)	45 (88)	43 (84)
AS duration, y, mean (SD)	7.5 (8.1)	5.4 (6.1)
Swollen joints ≥1, n (%)	30 (59)	33 (65)
BASDAI score, mean (SD)	6.8 (1.3)	6.6 (1.3)
CRP, mg/dl, mean (SD)	1.7 (1.8)	1.6 (2.2)
CRP, mg/dl, median	1.1	0.8

BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C reactive protein; TCZ, tocilizumab.